Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma Patients
Author:
Affiliation:
1. Hematology Department, Kitano Hospital, the Tazuke Kofukai Medical Research Institute
Publisher
Japanese Society for Lymphoreticular Tissue Research
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jslrt/56/1/56_50/_pdf
Reference22 articles.
1. 1 Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Group d’Etudes des Lymphomes del’ Adulte. Blood 116:2040-2045, 2010
2. 2 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
3. 3 Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 377:42-51, 2011
4. 4 Nastoupil LJ, Sinha R, Byrtek M , Zhou X, Taylor MD, et al.: The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 120:1830-1837, 2014
5. 5 Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, et al.: Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica 100:955-963, 2015
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ifosfamide-induced nephrotoxicity in oncological patients;Expert Review of Anticancer Therapy;2023-11-30
2. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial;Genome Medicine;2020-04-30
3. Comparison of Various Hematopoietic Stem Cell Mobilization Regimens in Patients with Lymphoma and Myeloma;Clinical Laboratory;2019
4. Epirubicin/etoposide/ifosfamide;Reactions Weekly;2017-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3